Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 9/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 6/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4186078 | 0.80 | SIGMAR1 (0.48) | KCNA5SIGMAR1 | |
| SCHEMBL4198014 | 0.78 | KCNA5 (0.42) | KCNA5SIGMAR1DRD4DRD2DRD3 | |
| SCHEMBL4198012 | 0.78 | KCNA5 (0.42) | KCNA5SIGMAR1DRD4DRD2DRD3 | |
| SCHEMBL4186053 | 0.77 | EPHX2 (0.44) | KCNA5SIGMAR1DRD4DRD2DRD3 | |
| SCHEMBL4186056 | 0.77 | EPHX2 (0.44) | KCNA5SIGMAR1DRD4DRD2DRD3 | |
| SCHEMBL4180562 | 0.73 | ABCB1 (0.42) | KCNA5SIGMAR1DRD4DRD2DRD3 | |
| SCHEMBL4180566 | 0.73 | ABCB1 (0.42) | KCNA5SIGMAR1DRD4DRD2DRD3 | |
| SCHEMBL4178692 | 0.71 | KCNA5 (0.46) | KCNA5SIGMAR1 | |
| SCHEMBL4178689 | 0.71 | KCNA5 (0.46) | KCNA5SIGMAR1 | |
| SCHEMBL5832019 | 0.69 | CCR3 (0.52) | SIGMAR1DRD4DRD3LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273905-B2 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | ABBOTT PRODUCTS GMBH (DE) | 2012-09-25 | — | — | US | disclosed |
| US-8273905-B2 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | ABBOTT PRODUCTS GMBH (DE) | 2012-09-25 | — | — | US | disclosed |
| US-7714150-B2 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714150-B2 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20090203686-A1 | Aminoalkyl-Amidomethyl-Substituted 2-(4-Sulphonylamino)- 3-Hydroxy-3,4-Dihydro-2H-Chroman-6-yl Derivatives | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20090203686-A1 | Aminoalkyl-Amidomethyl-Substituted 2-(4-Sulphonylamino)- 3-Hydroxy-3,4-Dihydro-2H-Chroman-6-yl Derivatives | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203686-A1 | Aminoalkyl-Amidomethyl-Substituted 2-(4-Sulphonylamino)- 3-Hydroxy-3,4-Dihydro-2H-Chroman-6-yl Derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9, ARG1 | KCNA5 1080/4885SIGMAR1 127/4885DRD4 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.